Co-Diagnostics Partners with Maxim Group to Explore SPAC Deal for Indian Joint Venture, CoSara Diagnostics Pvt. Ltd.

Written by Emily J. Thompson, Senior Investment Analyst

CODX.O-3.1%

Source: Newsfilter

Updated: Nov 05 2025

0mins

Source: Newsfilter

Co-Diagnostics Engages Financial Advisor: Co-Diagnostics, Inc. has appointed Maxim Group LLC as its exclusive financial advisor to explore strategic alternatives for its Indian joint venture, CoSara Diagnostics Pvt. Ltd., including a potential merger with a SPAC.
CoSara's Mission and Background: CoSara, established in 2017 as a joint venture between Co-Diagnostics and Synbiotics Ltd., aims to manufacture and sell molecular diagnostics products, initially focusing on the Indian market.
Company Overview: Co-Diagnostics, Inc. specializes in developing advanced molecular diagnostic tests and technologies, including tests for detecting nucleic acid molecules and genetic markers.
Forward-Looking Statements and Risks: The press release includes forward-looking statements about potential strategic transactions and product development, highlighting associated risks and uncertainties that could impact actual outcomes.

CODX.O

$0.0000%Past 6 months

Line

Candle

YTD

No Data

Intellectia

Analyst Views on CODX

About CODX

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

About the author

Preview

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.